Home » PAR'S GENERIC PARNATE RECEIVES FDA APPROVAL
PAR'S GENERIC PARNATE RECEIVES FDA APPROVAL
July 12, 2006
The FDA has approved Par Pharmaceutical's generic equivalent of GlaxoSmithKline's depression drug Parnate, the drugmaker said. Par will market the drug in 10-mg tablets.
Annual sales of Parnate (tranylcypromine sulfate) exceed $6 million, Par said.
Parnate was one of 11 antidepressants given a black box warning in January 2005 after the FDA approved labeling revisions to antidepressants to describe the increased risk of suicidal behavior in children and adolescents who take the drugs.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct